BXCL702

BXCL702 is a small molecule immunomodulator developed by BioXcel Therapeutics for oncology indications. It acts as an inhibitor of dipeptidyl-peptidase and tripeptidyl-peptidase enzymes, specifically targeting DPP4, DPP8, DPP9, and fibroblast activation protein (FAP). The drug is designed to modulate the tumor microenvironment by inhibiting these peptidases; inhibition of DPP8/9 induces proinflammatory cytokines while FAP inhibition disrupts tumor-stromal interactions. Preclinical studies have shown that BXCL702 can enhance immune cell infiltration into tumors and may synergize with checkpoint inhibitors such as pembrolizumab. The drug has been investigated in hematological malignancies (acute myeloid leukemia and diffuse large B-cell lymphoma) and solid tumors[1][2][6].